Member Info for amones

Perhaps, competition is one of the reasons why AZN has been working alongside Hutchmed (Savannah and Saffron studies to check the effectiveness of Orpathys + Tagrisso combination therapy). Marketing approval for O+T combination therapy will be a great achievement for HCM.

AZN has joined hands with HCM for getting approval for Tagrisso + Orpathys (Savolitinib). NDA been accepted in China for this combination therapy as per the latest news release from Hutchmed. End of this month, we might get some more information about the approval.

Compoundingm, does that clinical study compare J&J’s new drug combination with Tagrisso + Savolitinib combination? I can’t open that link. Link heading doesn’t seem to mention Savolitinib.

Share price neither needs a reason nor time to keep going in the downward direction.

HKSE aggregated shorts positions available for 27th December. There has been a further reduction of 300k. Good sign.

With some 27 million shares traded on the 2nd Jan, corresponding to the double news of divestment bringing in USD 608 million to the company and that of NDA acceptance for Tagrisso + orpathys. I am guessing further closures of short positions on the 2nd (and today as well ). New year has shown a bit of optimism.

Announcement of first ever cash dividend would be a welcome news. Company has enough cash in the bank. Hopefully a sensible analyst will be making an enquiry.

Very likely a major chunk of 26 million shares traded today was meant to close short positions.

More than 23 million shares traded within few hours at HKSE following news of NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination. It is also mentioned about a milestone payment to HCM from AZN.

Hoping for the opening sp to be in the blue at HKSE in the morning, following SHPL announcement earlier today. Added to that news is little bit of reduction in the reported short position. (20th December 15.5 millions, nearly 3 million less compared to 6th December)

What could be the thoughts of all those Asian investors who bought “lucky” 0013.HK during initial listing at HKSE, 4years ago? I think, most of the initial investors paid nearly/ over 3 times of today’s sp. From this side of the globe, let us hope that their belief about number 13 being lucky and auspicious, would come true in 2025.

As usual, so far, not a single word of concern about the poor share price from anyone in the management. Same question again; even at this super low valuation, why has this company not been able to attract any major players?

(Btw, for the past few weeks, I am observing share price graph of innovent (1801.HK). It looks very much similar to that of 0013.HK and each graph can be super imposed over the other!)

While the company’s managers engaged in releasing number of great deals and news, the share price is tumbling and struggling to find a bottom. Every trading day, there’s a new bottom. How low would it go?

It has become a routine; following news of positive outcome or progress, sp perks up for few days and invariably starts going down. Hope it is going to be different this time.

Pencil, short sellers are definitely aware of

Mr Buffett’s statement. But, why such significant increase in shorts volume with over the last 6 six weeks, that too in the midst of several encouraging news items? If one checks short positions data on SFC HK, there has been significant additions week after week. That is really a matter of concern for long time holders.

Directors buying and/or shares buy back can help to push up market valuation.

Aggregated short position as of 6th December (SFC, Hong Kong) is 18.34 million. It was 12.5m in end of October, ie., additional 6 million shares short sold in six weeks. What is encouraging the short sellers? Surely, they are not gullible like ordinary investors.

After US and Spain, HCM will be expecting similar milestone payments from sales in Switzerland (approved in August 2024), Canada, Japan and the United Kingdom (September 2024) , Argentina, Australia and Singapore (October 2024). Also applications supposedly progressing in many other countries.

(Jatw, is NICE yet to make a final decision? As per info from HCM company website, it’s already been approved in the UK)

Shame this company’s share price has fallen by 25% during the last 3 months. On one hand, shareholders holders see continuous drip feeding of “news of achievements” and on the other hand, have to witness falling market valuation. It doesn’t make any sense, to say the least!

Gone are the good old days when shareholders were encouraged with news of directors and board members buying huge numbers of shares in the open market. At least, company can buy back stocks so as to discourage the short sellers. Also, such news might help to clear the pessimism among investors.

Recent update on short positions shows additional half a million shares added during last week of November. What is happening with this stock? Investors are only given news about R&D achievements, approvals for new drug s and marketing successes. However, nobody speaks about the poor share and low market valuation. Has any one asked the CEO about this, in open sessions/meetings ?

Pencil, thanks for showing the numbers.

A very simple question; sp has dropped by more than 15% from the recent heights. Is there any reason or negative news to support this drop in sp? None at all.

On the other hand, every news item has been positive. What source of information does the short sellers relying on? Are the short sellers taking blind gambling risk and increasing short numbers by 4 millions in 3 weeks time? Looking at the sp movement, it wouldn’t be a surprise if the short numbers being much higher in the next update. Management has a responsibility towards supporting the investors.

Pencil, Short number stands at 16.95 million as per sfc.hk data on 22/11. It has increased by nearly 4 million in just 3/4 weeks time.

Management is surely aware of this. Short sellers seem to have gained lots of confidence, that too in the midst of news of Takeda starting to market fruzaqla in Japan! What exactly wrong with this stock?

Did you post recently that Chinese authorities have abolished short selling of China based companies’ stocks? If so, HKSE must be outside their control.

As jatw has written, shareholders need to have lots and lots of patience.

Thanks JatW, for taking time to post a detailed response. Very much appreciate your thorough analysis.

During 2017-21, for four years period, share price was at least 40% -50% higher than prevailing sp. During those days, drugs that are being marketed today were still either in R&D or in the pipeline. Presently, Hutcmed has been successful in obtaining number of approvals and marketing contracts in several countries. As you have correctly noted, markets have failed to give a correct valuation to HCM (remains below USD 3 billion while having a cash balance of USD 800 million). What annoys the shareholder is the ever increasing short volume pushing the sp way below 3 GBP/ 27 HK$. For some unknown reasons (to ordinary shareholders), short sellers seem to be very confident!

You have mentioned about repeated failures in obtaining approvals, I can remember only about Surufatinib with FDA and EMA (due to lack of clinical data involving non chinese patient population, which has lead to fresh clinical trials. Results of the same should be published in the coming days).

Finally, on a rare day when sp is going up, trade volume at HKSE touches 5-6 million. Can we take it as some kind of optimism?

Pencil, I have not send any emails to the IRO in the recent months.

Another welcome news. Good to know everything working as planned. Gaining regular income from marketing and licensing its products. Latest financial results show cash balance of $800 millions.

But, why is this company’s share price and market valuation not going up? SP declines to stay above £ 3. Whenever sp goes above £3 following good news item, it invariably goes down without any negative news.

Who cares for the investors? Btw, has anyone contacting investors’ relations, successful in receiving reassuring replies? Further increase in short volume as per latest data. Frustrating!